Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, August 19 at 2:00 PM EDT

Register Free →

Technical Data Acquisition & Reverse Engineering

Active
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

Agency

Department Of Defense → Ok DLA Aviation At Oklahoma CityView Agency

NAICS

541711 - Research and Development in BiotechnologyView NAICS

Place of Performance

OK, USA

Set-Aside

NONE

Documents

This scope was carved out of FD20302700209.

The full solicitation package (1 document), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

RETAINER, TURBINE BL_End_Item_F100_NSN_2840015824944NZ_PN_4089038

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

subcontract

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → Ok DLA Aviation At Oklahoma City
ContactsNo contacts available
OfficeN/A
Organization / Agency
Department Of Defense → Ok DLA Aviation At Oklahoma City
View Agency Profile
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Independent acquisition of engineering drawings and technical specifications, including reverse engineering if no Engineering Data List is provided.

Similar Contracts

Same NAICS industry code

NAICS: 541711
Federal
Integrated Phase I/II Clinical Trial DesignThe contract seeks the design and protocol development for an integrated Phase I/II clinical trial to evaluate ibogaine as a potential treatment for opioid use disorder, focusing on safety, optimal dosing, and therapeutic efficacy. The effort requires a comprehensive clinical framework that seamlessly merges the objectives of Phase I, which prioritizes dose escalation and toxicity profiling, with those of Phase II, which assesses preliminary effectiveness in reducing opioid dependence and withdrawal symptoms. The protocol must adhere to rigorous scientific and regulatory standards, incorporating appropriate patient selection criteria, monitoring procedures, endpoints, and risk mitigation strategies for a substance with significant pharmacological and safety considerations. The work is being pursued as a subcontract under the Advanced Research Projects Agency for Health, part of the Department of Health and Human Services, with a NAICS code indicating research and development in the life sciences. The solicitation was posted on August 5, 2026, and responses are due by October 15, 2026. The project is situated within a broader initiative to advance novel therapeutic interventions for the opioid crisis, requiring innovative trial design that balances exploratory research with clinical feasibility. There is no specified set-aside designation or location restriction for performance, indicating flexibility in execution while emphasizing scientific merit and regulatory alignment as key evaluation criteria.
Advanced Research Projects Agency For Health (arpa-H)

POSTED

8 days ago

DEADLINE

in 2 months
View Details

More opportunities from Department Of Defense → Ok DLA Aviation At Oklahoma City

Same awarding agency